On Tuesday, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Moderna, Inc.'s (NASDAQ: MRNA) updated COVID-19 vaccine, which targets the JN.1 variant of SARS-CoV-2.
Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19.
For the first time in the U.K., the updated vaccine, Spikevax JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program.
The updated vaccine will be available from high street pharmacies, occupational health providers, and private healthcare companies.
Sunday, the Taiwan Food & Drug Administration approved an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1., for active immunization in individuals six months of age and older.
Recently, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.
The updated vaccines from Moderna and Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) were approved.
In August, the European Commission approved Moderna's mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults 60 years and older from lower respiratory tract disease caused by RSV infection.
Price Action: MRNA stock is down 4.54% at $73.89 at the last check on Tuesday.